Wender M, Tokarz-Kupczyk E, Mularek O, Sniatała-Kamasa M
Kliniki Neurologii AM, Poznaniu.
Neurol Neurochir Pol. 1991 May-Jun;25(3):307-13.
A group of 21 patients with clinically confirmed multiple sclerosis were treated for one year with azathioprine, Germed, in daily doses of 50 or 75 mg depending on body weight. After two months the treatment was stopped for one month. The control group received prednisone (Encorton, Polfa) 5 or 10 mg daily. The drugs were given in wafers in powdered form. The double blind method was used. After one year the comparison of both groups failed to show any significant differences, and the reduction in the indices of exacerbations and stabilization of the process evaluated by Kurtzke's scale were nearly identical. However, this might have been due to the fact that nearly one-third of the patients dropped out from both groups. During the treatment with azathioprine no significant differences were noted in the surface phenotypes of peripheral blood mononuclear cells.
一组21例临床确诊为多发性硬化症的患者接受硫唑嘌呤（Germed）治疗一年，根据体重每日剂量为50或75毫克。两个月后治疗停止一个月。对照组每日接受泼尼松（Encorton，Polfa）5或10毫克。药物以粉末状薄片形式给药。采用双盲法。一年后两组比较未显示出任何显著差异，通过库尔特克量表评估的病情加重指数降低和病情稳定情况几乎相同。然而，这可能是由于两组中近三分之一的患者退出研究。在硫唑嘌呤治疗期间，外周血单个核细胞的表面表型未观察到显著差异。
